Research synthesisHigh evidenceModerate effect6 studies · 5 beneficial · 1 neutral · 0 harmful
Across 6 studies, 5 report beneficial effects of L-Carnitine supplementation on reducing C-Reactive Protein (CRP) levels, with 1 study showing neutral results and none showing harm. The predominant effect size is moderate, supported by meta-analyses (up to 3,255 participants) showing statistically significant reductions. Effects were observed across diverse clinical populations (e.g., migraine, sepsis, COVID-19), typically at doses of 2-3 g/day, with a median study duration of 46 days, suggesting benefits can appear within weeks.
- Effective dose range: 2-3 g/day
- Studied populations: Adults with migraine, critically ill septic patients, patients with mild-to-moderate COVID-19, adults with impaired glucose tolerance or diabetes, NAFLD patients (though neutral in this group)
Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). The only neutral study was a small pilot in NAFLD patients (n=22), which may reflect a lack of effect in that specific population or insufficient power. Doses and forms varied across studies, with limited reporting on supplement form, so it is unclear if certain forms are more effective.
Generated Jun 12, 2026